Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

ALE.P02 involves a CLDN-1-targeted antibody linked to a tubulin inhibitor, and ALE-P03 involves a CLDN-1-targeted antibody linked to a topoisomerase I inhibitor. OrbiMed, Novo Holdings, and Jeito ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

HDP-201, Heidelberg Pharma’s first Exatecan-based ADC candidate, is a topoisomerase I inhibitor that has proven success in cancer therapy and is already used in two approved ADCs. Its distinct mode of ...

ACE inhibitors are best known for treating high blood pressure. They work by targeting the hormone angiotensin II. Angiotensin-converting enzymes (ACE) inhibitors help blood vessels to relax and open.

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

Also known as selective COX-2 inhibitors, these medications treat inflammatory pain. Selective COX-2 inhibitors are a type of nonsteroidal anti-inflammatory medication (also known as NSAIDs).

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 ...

Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed ...